← Back to home

Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa)

Clinical trials sponsored by Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa), explained in plain language.

Now part of Merck & Co., Inc. MRK NYSE

Biopharmaceutical company focused on targeted cancer therapies, now a subsidiary of Merck.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1

New pill shows promise for Hard-to-Treat blood cancers

Disease control Ongoing

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

Phase: PHASE1, PHASE2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control

Last updated Jun 27, 2026 13:06 UTC

Arqule, Inc., A Subsidiary Of Merck Sharp & Dohme Llc, A Subsidiary Of Merck & Co., Inc. (rahway, Nj Usa)

New pill shows promise for Hard-to-Treat blood cancers